Granite Point Capital Management, L.P. Ovid Therapeutics Inc. Transaction History

Granite Point Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$2.03 - $4.35 $706,973 - $1.51 Million	-348,263 Closed	0 $0
Q3 2019 Oct 30, 2019	SELL	$1.76 - $3.51 $122,485 - $244,274	-69,594 Reduced 16.65%	348,263 $1.13 Million
Q1 2019 May 14, 2019	BUY	$1.77 - $3.56 $739,606 - $1.49 Million	417,857 New	417,857 $740,000
Q4 2018 Feb 05, 2019	SELL	$2.42 - $6.6 $270,618 - $738,051	-111,826 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$5.6 - $11.0 $936,398 - $1.84 Million	-167,214 Reduced 59.92%	111,826 $634,000
Q2 2018 Aug 13, 2018	BUY	$6.16 - $10.14 $1.64 Million - $2.71 Million	266,840 Added 2187.21%	279,040 $2.18 Million
Q1 2018 May 15, 2018	SELL	$6.53 - $9.82 $18,284 - $27,496	-2,800 Reduced 18.67%	12,200 $86,000
Q4 2017 Feb 08, 2018	BUY	$6.12 - $12.31 $91,800 - $184,650	15,000	15,000 $148,000

39.2M

10.3K

200

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $81M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.